While hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS), safety concerns have driven research toward nonhormonal alternatives. Recent advances highlight neurokinin receptor antagonists such as fezolinetant —FDA approved in 2023—and elinzanetant , currently under review, both offering rapid VMS relief without hormonal exposure. Another promising option, estetrol (E4) , a naturally derived estrogen unique to pregnancy, provides VMS and bone benefits with a favorable metabolic and breast safety profile.
Oxybutynin , traditionally used for overactive bladder, also shows efficacy against VMS but requires caution due to long-term cognitive risks. Together, these emerging therapies expand individualized treatment options for women unable or unwilling to use HT. To read more ; Click here Are neurokinin antagonists and estetrol ushering in a safer, more…
